Richard Pulik, an officer and director of Roivant Sciences Ltd., filed a Form 144 notice on November 12, 2026, disclosing a proposed sale of 175,000 shares of common stock on NASDAQ:ROIV with an aggregate market value of $7,323,568.07.

Key Highlights

  • Proposed sale: 175,000 shares of Roivant Sciences Ltd. common stock with an aggregate market value of $7,323,568.07, with an approximate sale date of November 11, 2026.
  • Seller: Richard Pulik, identified in the filing as both an officer and a director of the issuer.
  • Shares outstanding: 724,561,460 shares of common stock outstanding, according to the filing.
  • Prior sales: Pulik sold 125,000 shares on November 10, 2026, for gross proceeds of $5,150,575.00, as reported in the past-three-months sales table.
  • Source of shares: The proposed shares originate from multiple restricted stock vestings under a registered plan dating from June 30, 2023 through September 28, 2025, plus 127,365 shares from an exercise of options under a registered plan on November 11, 2026.
  • Filing note: According to the filing's remarks, "Sales that were executed on November 11, 2026 are being reported on this Form 144 filed on November 12, 2026 given the EDGAR system was not accepting filings on November 11, 2026 in observance of the federal holiday."

Pulik's Proposed Share Sale: Acquisition History and Recent Transactions

According to the Form 144 notice, Richard Pulik intends to sell 175,000 shares of Roivant Sciences Ltd. (NASDAQ:ROIV) common stock through Morgan Stanley Smith Barney LLC Executive Financial Services, located at 1 New York Plaza, 8th Floor, New York, NY 10004. The filing lists an approximate sale date of November 11, 2026, and reports the aggregate market value of the proposed sale at $7,323,568.07.

The filing details the acquisition history of the securities to be sold. The shares were accumulated through a series of restricted stock vestings under a registered plan, with individual vesting events recorded between June 30, 2023 and September 28, 2025, covering amounts ranging from 1,183 to 6,185 shares per event and paid for through services rendered. Additionally, 127,365 shares were acquired on November 11, 2026, via the exercise of options under a registered plan, for cash consideration, also from the issuer.

In the three months prior to the notice date, the filing discloses that Pulik sold 125,000 shares on November 10, 2026, generating gross proceeds of $5,150,575.00. The filing does not indicate the existence of a Rule 10b5-1 written trading plan. Pulik signed the notice on November 12, 2026, representing, as required by the form, that he is not aware of any material adverse information regarding the issuer's current and prospective operations that has not been publicly disclosed.

What Was Disclosed

Roivant Sciences Ltd. officer and director Richard Pulik filed a Form 144 on November 12, 2026, proposing to sell 175,000 common shares with an aggregate market value of $7,323,568.07, sourced from restricted stock vestings and an option exercise, with 724,561,460 shares currently outstanding.